Albumin-recruiting lipid nanoparticle potentiates the safety and efficacy of mRNA vaccines by avoiding liver accumulation
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The advent of mRNA vaccines represents a breakthrough in the realm of cancer therapy and the prevention of infectious disease. Nevertheless, traditional lipid nanoparticle (LNP)-based mRNA vaccines can accumulate in the liver post-intramuscular injection, posing a risk of hepatotoxicity and reducing efficacy. Here we develop an albumin-recruiting LNP system with high lymphatic drainage and no accumulation in hepatic tissue to potentiate the efficacy and safety of mRNA vaccines. We construct a library of ionizable lipids with albumin-binding capacity as alternatives to traditional polyethylene-glycol-conjugated lipid. We identify an Evans blue-modified lipid-based LNP (EB-LNP) formulation that shows high in vivo expression, albumin-facilitated transport through intramuscular lymphatic vessels to the lymph nodes, high internalization by dendritic cells and low penetration into intramuscular blood vessels, thereby avoiding liver accumulation. EB-LNP-based mRNA vaccines demonstrate excellent antitumour and antiviral efficacy, resulting in strong cellular and humoral immune responses, including the robust activation of cytotoxic T lymphocytes and production of neutralizing antibodies post-vaccination. Overall, this system shows promise as an effective and minimally toxic platform for the development of mRNA vaccines with high efficacy and safety.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A critical but underexplored determinant of LNP biodistribution is the protein corona, the dynamic layer of plasma proteins adsorbed onto nanoparticle surfaces upon entry into the bloodstream, which fundamentally dictates receptor interactions, cellular uptake pathways, and organ-level distribution [20][21][22] .”
From High-density Lipoprotein Inspired Lipid Nanoparticles for Systemic RNA delivery to the Brain (2026) · cites this paper as [22]
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 1×
“The invention and development of the lipid nanoparticle (LNP) delivery system represent milestones in the widespread application of mRNA vaccines 1,2 .”
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383 · cited 1×
“Researchers have focused on developing various ionizable and cationic lipids 21,22 , yet challenges remain in creating delivery systems with high efficacy and low hepatotoxicity.”
The entry of nanoparticles into solid tumours
Sindhwani, S., Syed, A. M., Ngai, J., Kingston, B. R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N. U., Hoang, T., et al. (2020) · Nature Materials · doi:10.1038/s41563-019-0566-2 · Cited by 1,732 · cited 2×
“42).”
Dynamics of B cells in germinal centres
De Silva, N. S., & Klein, U. (2015) · Nature Reviews Immunology · doi:10.1038/nri3804 · Cited by 1,084
On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles
Dilliard, S. A., Cheng, Q., & Siegwart, D. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2109256118 · Cited by 1,018 · cited 1×
“The rapid shedding of PEG-lipid and the recruitment of apolipoprotein E (ApoE) after intramuscular (i.m.) injection can lead to considerable internalization by hepatocytes through low-density-lipoprotein-receptor-mediated endocytosis 26 .”
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Weber, J. S., Carlino, M. S., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M. H., Kim, K. B., McKean, M., Long, G. V., Sullivan, R. J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02268-7 · Cited by 916
BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Ndeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., & Igyártó, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103479 · Cited by 678
Research works printed but not linked: 41
- Pardi, N. & Krammer, F. mRNA vaccines for infectious diseases—advances, challenges and opportunities. Nat. Rev. Drug. Discov. 23, 838–861 (2024). · DOI · Paper page
- Ju, Y. et al. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. Nat. Rev. Immunol. 23, 135–136 (2023). · DOI · Paper page
- Chen, J. et al. Current developments and challenges of mRNA vaccines. Annu. Rev. Biomed. Eng. 24, 85–109 (2022). · DOI
- Pateev, I. et al. Biodistribution of RNA vaccines and of their products: evidence from human and animal studies. Biomedicines 12, 59 (2023). · DOI
- Ye, Z. et al. Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants. Proc. Natl Acad. Sci. USA 120, e2311752120 (2023).
- Shi, Y. et al. Structural and biochemical characteristics of mRNA nanoparticles determine anti-SARS-CoV-2 humoral and cellular immune responses. Sci. Adv. 8, eabo1827 (2022). · DOI
- Chen, J. et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proc. Natl Acad. Sci. USA 119, e2207841119 (2022).
- Kitagawa, H. et al. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. J. Infect. Chemother. 28, 576–581 (2022). · DOI
- Schinas, G. et al. Immune-mediated liver injury following COVID-19 vaccination. World J. Virol. 12, 100–108 (2023). · DOI
- Efe, C. et al. Liver injury after SARS-CoV-2 vaccination: features of immune-mediated hepatitis, role of corticosteroid therapy and outcome. Hepatology 76, 1576–1586 (2022). · DOI · Paper page
- Boettler, T. et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. J. Hepatol. 77, 653–659 (2022). · DOI
- Zin Tun, G. S. et al. Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed. J. Hepatol. 76, 738–753 (2022). · DOI
- Jeong, M. et al. Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications. Adv. Drug Deliv. Rev. 200, 114990 (2023). · DOI · Paper page
- Liu, M. et al. Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy. Sci. Adv. 10, eadk2444 (2024). · DOI
- Sasaki, K. et al. mRNA-loaded lipid nanoparticles targeting dendritic cells for cancer immunotherapy. Pharmaceutics 14, 1572 (2022). · DOI
- Yu, X. et al. Poly(ethyl ethylene phosphate): overcoming the ‘polyethylene glycol dilemma’ for cancer immunotherapy and mRNA vaccination. ACS Nano 17, 23814–23828 (2023). · DOI
- Hald Albertsen, C. et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv. Drug Deliv. Rev. 188, 114416 (2022). · DOI · Paper page
- Tenchov, R. et al. PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective. Bioconjug. Chem. 34, 941–960 (2023). · DOI · Paper page
- Elzoghby, A. O. et al. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Control. Release 157, 168–182 (2012). · DOI · Paper page
- Abdallah, M. et al. Lymphatic targeting by albumin-hitchhiking: applications and optimisation. J. Control. Release 327, 117–128 (2020). · DOI · Paper page
- Famta, P. et al. Albumin-hitchhiking: fostering the pharmacokinetics and anticancer therapeutics. J. Control. Release 353, 166–185 (2022). · DOI · Paper page
- Qi, S. et al. The bright future of nanotechnology in lymphatic system imaging and imaging-guided surgery. J. Nanobiotechnol. 20, 24 (2022). · DOI
- Zhu, G. et al. Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nat. Commun. 8, 1954 (2017).
- Um, W. et al. A comparative study on albumin-binding molecules for targeted tumor delivery through covalent and noncovalent approach. Bioconjug. Chem. 30, 3107–3118 (2019). · DOI
- Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519–522 (2014). · DOI · Paper page
- Song, Y. et al. Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice. Sci. Transl. Med. 14, eabl3649 (2022). · DOI
- Lin, T. et al. Blood–brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy. ACS Nano 10, 9999–10012 (2016). · DOI · Paper page
- Liu, Z. & Chen, X. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem. Soc. Rev. 45, 1432–1456 (2016). · DOI · Paper page
- Liu, Y. et al. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nat. Nanotechnol. 17, 206–216 (2022). · DOI
- Bern, M. et al. The role of albumin receptors in regulation of albumin homeostasis: implications for drug delivery. J. Control. Release 211, 144–162 (2015). · DOI · Paper page
- Ishima, Y. et al. The new delivery strategy of albumin carrier utilizing the interaction with albumin receptors. Chem. Pharm. Bull. 70, 330–333 (2022). · DOI
- Wan, Y. et al. Stable organic photosensitizer nanoparticles with absorption peak beyond 800 nanometers and high reactive oxygen species yield for multimodality phototheranostics. ACS Nano 14, 9917–9928 (2020). · DOI · Paper page
- Nguyen, L. N. M. et al. The exit of nanoparticles from solid tumours. Nat. Mater. 22, 1261–1272 (2023). · DOI · Paper page
- Embgenbroich, M. & Burgdorf, S. Current concepts of antigen cross-presentation. Front. Immunol. 9, 1643 (2018). · DOI · Paper page
- Oğuz, F. & Atmaca, H. mRNA as a therapeutics: understanding mRNA vaccines. Adv. Pharm. Bull. 12, 274–282 (2022).
- Szymonowicz, K. A. & Chen, J. Biological and clinical aspects of HPV-related cancers. Cancer Biol. Med. 17, 864 (2020). · DOI · Paper page
- Mirabello, L. et al. HPV16 E7 genetic conservation is critical to carcinogenesis. Cell 170, 1164–1174 (2017). · DOI · Paper page
- Feshchenko, E. et al. Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability. BMC Biotechnol. 12, 77 (2012). · DOI
- Cyster, J. G. & Allen, C. D. C. B cell responses: cell interaction dynamics and decisions. Cell 177, 524–540 (2019). · DOI · Paper page
- Mittenbühler, M. J. et al. Isolation of extracellular fluids reveals novel secreted bioactive proteins from muscle and fat tissues. Cell Metab. 35, 535–549 (2023). · DOI
- Renier, N. et al. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell 159, 896–910 (2014). · DOI · Paper page
Cited by
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33
High-density Lipoprotein Inspired Lipid Nanoparticles for Systemic RNA delivery to the Brain
Xu, Z., Shalin, K., Do, V., Yan, A., & Gao, J. (2026) · doi:10.64898/2026.05.29.728695 · Cited by 1
Metadata
- Authors
- Feng, Y., Tai, W., Huang, P., Qi, S., Yu, X., Li, M., Li, M., Zhang, M., Cao, F., Gao, X., Yang, K., Bai, B., Lei, J., Cheng, M., Li, Y., Cheng, G., Chen, X., & Yu, G.
- Venue
- Nature Materials
- Published
- 2025-08-01
- Volume
- 24
- Issue
- 11
- Pages
- 1826-1839
- ISSN
- 1476-1122
- 1476-4660
- Cited by
- 66
- References
- 12
- Language
- en
- Update notices
- correction (2025-08-12)
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Funders
- National University of Singapore (NUHSRO/2020/133/Startup/08)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Albumin-recruiting lipid nanoparticle potentiates the safety and efficacy of mRNA vaccines by avoiding liver accumulation. https://app.cochat.ai/papers/10.1038/s41563-025-02284-w
- The paper
- Feng, Y., Tai, W., Huang, P., Qi, S., Yu, X., Li, M., Li, M., Zhang, M., Cao, F., Gao, X., Yang, K., Bai, B., Lei, J., Cheng, M., Li, Y., Cheng, G., Chen, X., & Yu, G. (2025). Albumin-recruiting lipid nanoparticle potentiates the safety and efficacy of mRNA vaccines by avoiding liver accumulation. Nature Materials. https://doi.org/10.1038/s41563-025-02284-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.